Biogen Inc. (BIIB) AI Stock Analysis

Biogen Inc. is a biopharmaceutical company that discovers, develops, and delivers therapies targeting neurological and neurodegenerative diseases. Its portfolio includes multiple sclerosis therapies such as TECFIDERA, AVONEX, and TYSABRI, as well as SPINRAZA for spinal muscular atrophy. Biogen is also advancing Alzheimer's disease treatments, including ADUHELM, and produces biosimilars such as BENEPALI and FLIXABI for inflammatory diseases. Founded in 1978 and based in Cambridge, Massachusetts, the company collaborates with global pharmaceutical partners and research institutions while pursuing pipeline candidates in neuromuscular disorders, Parkinson's disease, and immunology.

Biogen recorded a 5-year revenue CAGR of -6.1% from FY2020 to FY2025. Annual revenue decreased from $10.98B in FY2021 to $10.17B in FY2022, $9.84B in FY2023, and $9.68B in FY2024, before increasing 1.4% to $9.81B in FY2025. Net income was $1.29B in FY2025, down from $1.63B in FY2024 and $3.05B in FY2022. Gross margin contracted to 70.5% in FY2025 from 80.8% in FY2021, and operating margin was 19.1%. For the latest quarter ended June 30, 2026, revenue increased 3.4% year-over-year, while quarterly earnings dropped 84.8%. Trailing twelve-month revenue stood at $10.03B with an 8.3% profit margin.

As of June 30, 2026, Biogen held $1.28B in cash and short-term investments against total debt of $8.36B, resulting in net debt of $7.07B. Total assets were $32.09B and shareholders' equity was $18.85B, with a debt-to-equity ratio of 0.44 and a current ratio of 1.87. Free cash flow for FY2025 was $2.05B, supported by $2.20B in operating cash flow. In FY2025, capital expenditures were $153.8M, while its share count changed by 0.8% over five years.

Biogen trades at a trailing P/E of 41.3x, above the 27.2x median of its S&P 500 Healthcare peers. Its forward P/E is 13.9x compared to the peer median of 16.6x, and its EV-to-EBITDA stands at 19.0x versus the peer median of 15.0x. Price-to-sales matches the peer median at 3.4x. Over the past year, BIIB advanced 63.5%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return of -17.3% trails the benchmark's 83.0% gain.

Wall Street analysts hold 20 Strong Buy, 4 Buy, 11 Hold, 0 Sell, and 1 Strong Sell ratings on Biogen. Their mean price target of $243.98 implies 4.9% upside from the last close of $232.65. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $12.53, an 18.0% decline, on revenue of $10.44B. Next fiscal year estimates project EPS of $16.52 on revenue of $10.64B across 32 analysts. The company beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for October 28, 2026.

This page is an AI-written research summary of Biogen Inc. (BIIB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BIIB income statement, BIIB balance sheet, BIIB key metrics, BIIB analyst forecast, BIIB chart. See the BIIB stock overview for the latest quote and news.